🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 10 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 15/01/2020 | 229,88 | 234,33 | 228,78 | 234,15 | +1,92% | 2,41% | 1.741.500 |
| 14/01/2020 | 226,44 | 229,80 | 225,53 | 229,75 | +1,44% | 1,89% | 1.042.000 |
| 13/01/2020 | 229,38 | 230,00 | 224,56 | 226,49 | -1,07% | 2,37% | 1.031.500 |
| 10/01/2020 | 231,69 | 231,69 | 228,07 | 228,95 | -0,57% | 1,56% | 1.017.300 |
| 09/01/2020 | 233,08 | 233,26 | 227,27 | 230,26 | -0,36% | 2,57% | 1.435.400 |
| 08/01/2020 | 225,89 | 232,70 | 224,91 | 231,09 | +3,26% | 3,45% | 1.802.600 |
| 07/01/2020 | 224,26 | 225,92 | 222,14 | 223,79 | -0,11% | 1,69% | 1.027.700 |
| 06/01/2020 | 217,73 | 224,35 | 216,91 | 224,03 | +2,78% | 3,42% | 1.436.600 |
| 03/01/2020 | 216,16 | 219,89 | 214,55 | 217,98 | -0,67% | 2,47% | 943.400 |
| 02/01/2020 | 220,24 | 220,65 | 216,95 | 219,45 | +0,23% | 1,68% | 1.334.300 |
| 31/12/2019 | 218,60 | 219,81 | 216,70 | 218,95 | -0,01% | 1,42% | 1.036.400 |
| 30/12/2019 | 220,38 | 221,95 | 217,33 | 218,97 | -0,91% | 2,10% | 774.300 |
| 27/12/2019 | 220,59 | 221,48 | 218,12 | 220,97 | +0,33% | 1,52% | 904.600 |
| 26/12/2019 | 220,60 | 220,90 | 218,38 | 220,25 | -0,14% | 1,14% | 697.000 |
| 24/12/2019 | 220,46 | 220,64 | 218,51 | 220,56 | +0,26% | 0,97% | 300.500 |
| 23/12/2019 | 220,95 | 222,87 | 219,68 | 219,98 | -0,32% | 1,44% | 1.132.800 |
| 20/12/2019 | 219,62 | 221,02 | 217,00 | 220,69 | +1,34% | 1,83% | 2.824.100 |
| 19/12/2019 | 220,14 | 220,68 | 216,98 | 217,78 | -0,72% | 1,68% | 1.864.200 |
| 18/12/2019 | 217,83 | 219,92 | 217,49 | 219,35 | +0,79% | 1,12% | 1.759.400 |
| 17/12/2019 | 219,72 | 219,73 | 216,01 | 217,62 | -0,86% | 1,69% | 1.452.500 |
| 16/12/2019 | 220,50 | 221,86 | 219,33 | 219,50 | +0,24% | 1,15% | 1.919.300 |
| 13/12/2019 | 220,19 | 221,62 | 217,83 | 218,98 | -0,71% | 1,72% | 1.484.100 |
| 12/12/2019 | 219,71 | 222,55 | 219,17 | 220,55 | +0,25% | 1,54% | 1.094.600 |
| 11/12/2019 | 221,91 | 224,27 | 219,58 | 220,00 | -0,12% | 2,11% | 958.900 |
| 10/12/2019 | 219,42 | 221,87 | 218,50 | 220,27 | +0,41% | 1,54% | 1.256.600 |
| 09/12/2019 | 222,99 | 225,66 | 219,19 | 219,37 | -1,74% | 2,90% | 1.784.300 |
| 06/12/2019 | 224,17 | 224,66 | 220,36 | 223,25 | +0,08% | 1,92% | 1.021.300 |
| 05/12/2019 | 223,77 | 224,31 | 221,35 | 223,07 | -0,38% | 1,32% | 767.200 |
| 04/12/2019 | 222,00 | 224,08 | 221,07 | 223,91 | +1,26% | 1,36% | 937.000 |
| 03/12/2019 | 219,61 | 222,75 | 218,39 | 221,13 | +0,15% | 1,99% | 949.200 |